Research provides critical information about the size and growth speed of gliomas

An important new clue for preventing and treating brain tumors known as gliomas has been identified in research led by the Lunenfeld-Tannenbaum Research Institute (LTRI) at Mount Sinai Hospital in Toronto and Mayo Clinic Comprehensive Cancer Center and Mayo Clinic Center for Individualized Medicine. The study, published in the journal Science, provides a rare window into the biological changes behind glioma development.

Mayo Clinic receives first-of-its-kind accreditation for diagnosis of primary ciliary dyskinesia

Mayo Clinic’s Department of Laboratory Medicine and Pathology, the academic testing arm for Mayo Clinic Laboratories, has been accredited as a diagnostic site by the PCD Foundation. Mayo Clinic is the first and only center of excellence to receive PCD Foundation accreditation for the diagnosis of primary ciliary dyskinesia, a rare and debilitating lung disease.

Laboratorios de Mayo Clinic detectan nueva enfermedad autoinmunitaria vinculada al cáncer de testículo

Los Laboratorios de Mayo Clinic pusieron en marcha la primera prueba autoinmunitaria en su clase para el anticuerpo contra la proteína tipo Kelch 11 (KLHL11), que sirve para detectar una enfermedad autoinmunitaria relacionada con el cáncer de testículo. La prueba está disponible a nivel nacional e internacional.